疫苗诱导的免疫性血栓性血小板减少症
本文为观点文章,讨论疫苗诱导的免疫性血栓性血小板减少症(VITT)的流行病学、病理生理及诊断治疗管理。挪威、德国和英国三个科学小组报告了接种阿斯利康-牛津疫苗后出现脑静脉窦血栓伴血小板减少和抗血小板因子4(抗PF4)抗体,该综合征后续也见于强生疫苗接种者。疑似VITT者应尽快检测抗PF4抗体,并启动静脉注射免疫球蛋白和非肝素抗凝治疗。
要点
- 接种阿斯利康-牛津疫苗后出现脑静脉窦血栓伴血小板减少和抗PF4抗体,被命名为VITT。
- VITT也见于强生疫苗接种者。
- 疑似VITT应尽快检测抗PF4抗体,并予静脉注射免疫球蛋白和非肝素抗凝治疗。
核心结论
- 挪威、德国和英国三个科学小组报告接种阿斯利康-牛津疫苗后出现脑静脉窦血栓伴血小板减少和抗PF4抗体,并将该新综合征命名为VITT。
- 该综合征后续也见于强生疫苗接种者。
- 疑似VITT者应尽快检测抗PF4抗体,并启动针对自身免疫过程的静脉注射免疫球蛋白和针对促血栓过程的非肝素抗凝治疗。
研究设计与样本
- 本文为观点文章,讨论VITT的流行病学、病理生理及最佳诊断和治疗管理。
主要发现
- 挪威、德国和英国三个科学小组报告了接种阿斯利康-牛津疫苗后出现脑静脉窦血栓伴血小板减少和抗PF4抗体的个体。
- 该综合征后续在接种强生疫苗的个体中也有报告。
关键数值与推荐
- 出现疑似VITT表现时,应尽快检测抗PF4抗体,并启动静脉注射免疫球蛋白和非肝素抗凝治疗。
临床怎么用
- 出现疑似VITT表现时,应尽快检测抗PF4抗体,并启动针对自身免疫过程的静脉注射免疫球蛋白和针对促血栓过程的非肝素抗凝治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested, and introduced at a remarkable speed. Although the vaccine introduction had a major impact on the evolution of COVID-19, some potential rare side-effects of the vaccines were observed. Within a short period, three scientific groups from Norway, Germany, and the UK reported cerebral venous sinus thrombosis with thrombocytopenia and anti-platelet factor 4 (anti-PF4) antibodies in individuals following AstraZeneca-Oxford vaccination and named this new syndrome vaccine-induced immune thrombotic thrombocytopenia (VITT). This syndrome was subsequently reported in individuals who received Johnson & Johnson vaccination. In this Viewpoint, we discuss the epidemiology, pathophysiology, and optimal diagnostic and therapeutic management of VITT. Presentation of an individual with possible VITT should raise prompt testing for anti-PF4 antibodies and initiation of treatment targeting autoimmune processes with intravenous immunoglobulin and prothrombotic processes with non-heparin anticoagulation.
引用
- Klok FA, Pai M, Huisman MV, et al. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2021. PMID: 34774202. doi:10.1016/S2352-3026(21)00306-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。